mirogabalin and Herpes-Zoster

mirogabalin has been researched along with Herpes-Zoster* in 2 studies

Trials

1 trial(s) available for mirogabalin and Herpes-Zoster

Article	Year
Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study. British journal of clinical pharmacology, 2018, Volume: 84, Issue:10 The primary aim of this study was to assess the individual effects of probenecid and cimetidine on mirogabalin exposure.. This phase 1, open-label, crossover study randomized healthy adults to receive three treatment regimens, each separated by ≥5-day washout: a single oral dose of mirogabalin 15 mg on day 2, mirogabalin 15 mg on day 2 plus probenecid 500 mg every 6 h from days 1 to 4, and mirogabalin 15 mg on day 2 plus cimetidine 400 mg every 6 h from days 1 to 4.. Coadministration of mirogabalin with probenecid or cimetidine increased the maximum and total mirogabalin exposure. The geometric mean ratios of C. A greater magnitude of change in mirogabalin exposure was observed when coadministered with a drug that inhibits both renal and metabolic clearance (probenecid) vs. a drug that only affects renal clearance (cimetidine). However, as the increase in exposure is not clinically significant (>2-fold), no a priori dose adjustment is recommended. Topics: Administration, Oral; Adult; Area Under Curve; Bridged Bicyclo Compounds; Cimetidine; Cross-Over Studies; Diabetic Neuropathies; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Herpes Zoster; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neuralgia; Probenecid; Renal Elimination	2018

Article

Year

Coadministration of probenecid and cimetidine with mirogabalin in healthy subjects: A phase 1, randomized, open-label, drug-drug interaction study.

British journal of clinical pharmacology, 2018, Volume: 84, Issue:10

The primary aim of this study was to assess the individual effects of probenecid and cimetidine on mirogabalin exposure.. This phase 1, open-label, crossover study randomized healthy adults to receive three treatment regimens, each separated by ≥5-day washout: a single oral dose of mirogabalin 15 mg on day 2, mirogabalin 15 mg on day 2 plus probenecid 500 mg every 6 h from days 1 to 4, and mirogabalin 15 mg on day 2 plus cimetidine 400 mg every 6 h from days 1 to 4.. Coadministration of mirogabalin with probenecid or cimetidine increased the maximum and total mirogabalin exposure. The geometric mean ratios of C. A greater magnitude of change in mirogabalin exposure was observed when coadministered with a drug that inhibits both renal and metabolic clearance (probenecid) vs. a drug that only affects renal clearance (cimetidine). However, as the increase in exposure is not clinically significant (>2-fold), no a priori dose adjustment is recommended.

Topics: Administration, Oral; Adult; Area Under Curve; Bridged Bicyclo Compounds; Cimetidine; Cross-Over Studies; Diabetic Neuropathies; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Herpes Zoster; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neuralgia; Probenecid; Renal Elimination

2018

Other Studies

1 other study(ies) available for mirogabalin and Herpes-Zoster

Article	Year
Case of neuropathic itch-associated prurigo nodules on the bilateral upper arms after unilateral herpes zoster in a patient with cervical herniated discs: Successful treatment with mirogabalin. The Journal of dermatology, 2021, Volume: 48, Issue:12 Topics: Arm; Bridged Bicyclo Compounds; Herpes Zoster; Humans; Intervertebral Disc Displacement; Prurigo	2021